Balaji Amines Ltd Q2 FY2025 Concall Summary

Key Takeaways

• Margin resilience despite revenue dip: EBITDA margin improved 110 bps QoQ to 20% even as revenue fell to ₹356 cr, driven by a deliberate shift toward higher-margin products.
• Methyl Amine capacity doubles: The new 88,000-ton plant was commissioned on 10 November 2024, with 50–60% utilization targeted next year and 70–80% by FY26–27.
• DME is the wildcard: The Di-Methyl Ether plant commissions by end-FY25 or Q1 FY26, and management calls it a potential game changer as India's first LPG alternative, but refuses to quantify revenue or margins yet.
• Battery chemicals: demand still absent: EV battery manufacturers have not started operations despite 2–3 years of promises; one large player requested samples but has not even broken ground.
• What to watch next quarter: Whether DMF and EDA prices continue their recovery from Chinese-dumping lows, the DME blending notification from BIS, and any concrete progress on battery-chemical offtake.

Margin & Pricing Dynamics

• Product mix shift worked: EBITDA margin rose to 20% from 19% QoQ despite the revenue decline, and H1 FY25 standalone margin reached 19% versus 16% in H1 FY24, with PAT climbing to ₹81 cr from ₹67 cr.
• Pricing trough appears behind: Prices declined for two consecutive quarters, but most products are now settling; management expects realistic price increases by the end of the financial year.
• Chinese dumping receding: DMF, NMP and EDA prices hit rock bottom 4–6 months ago on heavy Chinese dumping and have now started recovering to realistic levels.
• Anti-dumping lever ready: Management will initiate anti-dumping duty again if prices continue to rise, possibly as early as next quarter.
• US/Europe opportunity: Anti-dumping duties imposed by the US and Europe on Chinese products are creating openings for cyanide-based intermediates.

Reddy: "If I say today 30%, immediately you will ask in the next quarter what happened to 30%? That is the reason I am not in a position to tell you."

Methyl Amine & the New DMA Technology

• Capacity doubled overnight: The state-of-the-art plant at Unit IV raised annual methyl amine capacity from 48,000 to 88,000 metric tons, commissioned on 10 November 2024.
• Utilization ramp laid out: 50–60% capacity utilization expected next year, scaling to more than 70–80% in FY26 and FY27, with full utilization anticipated by FY26–27.
• Single-product DMA capability: The new technology can produce 100–110 tons per day of pure DMA without co-producing MMA and TMA, a flexibility the old plant lacked.
• Volume growth anchored here: Management expects minimum 10–12% volume growth for FY25, with an additional 40,000–50,000 tons coming next financial year after DME and two other plants commission.

Reddy: "In this new plant, we can produce single DMA, 100 tons, 110 tons per day without producing other two products. That is the beauty of new technology."

DME: The LPG-Alternative Bet

• First-mover in India: DME is being introduced as an alternative to LPG for the first time in the country; the BIS notification for blending DME with LPG is at the final stage and expected by end of the month.
• Plant timeline: Commissioning projected by end of this financial year or Q1 of next financial year.
• Commercial LPG opportunity: More than 10,000–15,000 tons of demand exists across three districts; management believes the government will not obstruct supply to private players.
• Blending scale implies multi-plant need: If India mandates 20% blending, the country would need at least another 10 plants of this scale.
• Margins: deliberately unguided: Management calls it too early to quantify, needing 6–12 months of operations to ascertain actual margins, but eventually guided 18–22% EBITDA, at par with existing investments.

Reddy: "It's a product first time in the country and introduction as an alternate to the LPG also first time in the country. It will take some time, and it is too early to assume any numbers or any capacities. But definitely, we feel that it should be a game changer."

Battery Chemicals: The Waiting Game

• Demand still a promise, not a reality: Battery manufacturers have not commenced operations despite management hearing promises for 2–3 years; one large EV battery company requested samples and pricing but has not even started land digging.
• Realistic commercial activity: Management expects the first meaningful offtake no earlier than Q1 of next financial year, roughly 4–6 months out.
• NMP and DMC approved: NMP has been approved with two or three manufacturers who intend to use it; DMC is also approved, with battery-grade implementation expected to improve performance.
• Revenue potential unquantified: When pressed on what revenue battery chemicals could generate, management gave only a general update on approvals and electrolyte opportunities without attaching numbers.

Reddy: "Mukulji, we are also worried on this because battery manufacturers, nobody has started as of now. We are hearing this for last two to three years, we are hearing that today or tomorrow they will start."

CAPEX Pipeline & Balaji Specialty Chemicals

• BSCL Mega Project: The Government of Maharashtra granted mega project status under the Packaged Scheme of Incentives 2019, with a proposed phased investment of ₹750 cr.
• Phase-1 timeline: 2–3 plants to be commissioned in exactly 365 days from now (11–12 months); Phase-2 will take another 12 months from Phase-1 commencement.
• Product portfolio: Includes Hydrogen Cyanide, Sodium Cyanide (30% and 100%), EDTA, Disodium salt, Benzyl Cyanide, Phenylacetic Acid, Tri Ethyl Ortho Formate, and Tri Methyl Ortho Formate.
• Unit 1 de-bottlenecking: Work ongoing to produce more Piperazine, DETA, and new value-addition products like TETA; most EDA will be consumed internally; expected completion in 4–6 months.
• Acetonitrile plant: New 60 MTPD plant planned at Unit III; technology transfer discussions in final stages with agreement expected by end of November 2024.
• Other projects: Isopropyl Amines, N-Methyl Morpholine, and NBPT plants all scheduled for next financial year; Solar Power Plant Phase 1 (8 MW DC / 6 MW AC) and DMC/Propylene Glycol enhancement expected within this financial year.
• Debt-free commitment reaffirmed: Majority of expansions funded from internal accruals; management sees no rationale in sitting on cash.

Reddy: "We are not doing any big borrowings, and simply sitting on the cash will not give you any results, right? We are doing the majority of the expansions from the internal accruals and looking to the future thinking of the government, future policies of the government, we have designed."

Revenue Ambition & Volume Trajectory

• Standalone revenue target: ₹1,300–1,400 cr at current prices; ₹1,700–1,800 cr if prices improve.
• Medium-term aspiration: ₹3,000–4,000 cr in 2–2.5 years if prices return to realistic levels.
• Volume bridge: 10–12% volume growth this year, then an incremental 40,000–50,000 tons next financial year from DME and two other plant commissions.
• DMF utilization: Aiming for at least 80–85% capacity utilization for the remainder of the year.
• ACN rationale: Balaji was deliberately inactive in Acetonitrile because margins were very low and international competition was high; the company does not manufacture for the sake of volume.

Guidance & Commitments

Key Metrics